Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study.

Taşkıran E, Erdoğan MA, Yiğittürk G, Erbaş O

Cardiovascular toxicology1 Dec 2019Cited by 17 (Europe PMC)

PMID31054117DOI10.1007/s12012-019-09524-xPepBankPUB-31054117

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, liraglutide ameliorated the toxic effect of doxorubicin in cardiac tissue, with less powerful effects than oxytocin.
In plain wordsIn rats with doxorubicin heart damage, liraglutide reduced the damage to heart tissue, but less than oxytocin did.
Peptide
Liraglutide
Outcome
DecreaseDoxorubicin toxicity in cardiac tissue
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
DXR + saline (placebo)
Outcome group
Myocardial injury · Cardiovascular
Studied dose
1.8 mg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Source sentences
Summary
All three treatments were shown to ameliorate the toxic effect of doxorubicin in cardiac tissue with the best results in DXR + OX group.
4 context sentences(design, population, supporting numbers)
Summary · context
LIR and G-CSF treatment caused similar results with less powerful effects.
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411701
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, oxytocin ameliorated the toxic effect of doxorubicin in cardiac tissue, with the best results of the three treatments.
In plain wordsIn rats with doxorubicin heart damage, oxytocin reduced the damage to heart tissue, with the best results of the three treatments tested.
Peptide
Oxytocin
Outcome
DecreaseDoxorubicin toxicity in cardiac tissue
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
DXR + saline (placebo)
Outcome group
Myocardial injury · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Source sentences
Summary
All three treatments were shown to ameliorate the toxic effect of doxorubicin in cardiac tissue with the best results in DXR + OX group.
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411702
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the most preserved cardiac tissue integrity among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, heart tissue stayed in better shape with oxytocin than with liraglutide or G-CSF.
Peptide
Oxytocin
Outcome
IncreaseCardiac tissue integrity on light microscopy
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Myocardial injury · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Source sentences
Summary
DXR + OX group had the most preserved tissue integrity examined by light microscopy
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411703
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the lowest cardiac CASPASE-3 expression among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, oxytocin gave the lowest level of a cell-death marker in the heart among the three treatments.
Peptide
Oxytocin
Outcome
DecreaseCASPASE-3 immune expression
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Myocardial injury · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Source sentences
Summary
least immune expression level of CASPASE-3 (5.3 ± 0.9) (p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411704
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the highest ECG QRS wave voltage amplitude among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, the heart tracing (ECG) signal was strongest with oxytocin among the three treatments.
Peptide
Oxytocin
Outcome
IncreaseECG QRS wave voltage amplitude
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Heart function · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Measurements
QRS wave voltage amplitude
0.21 mV
DXR + OX
Source sentences
Summary
the highest ECG QRS wave voltage amplitude (0.21 ± 0.008 mV) (p < 0.00001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411705
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the lowest plasma MDA, a marker of oxidative stress, among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, oxytocin gave the lowest blood level of an oxidative stress marker among the three treatments.
Peptide
Oxytocin
Outcome
DecreasePlasma MDA
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Oxidative stress · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Measurements
Plasma MDA
115.3 nm
DXR + OX
Source sentences
Summary
least plasma MDA (115.3 ± 19.8 nm) (p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411706
07AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the lowest plasma TNF-alpha among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, oxytocin gave the lowest blood level of the inflammation marker TNF-alpha among the three treatments.
Peptide
Oxytocin
Outcome
DecreasePlasma TNF-alpha
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Measurements
Plasma TNF-alpha
26.6 pg/ml
DXR + OX
Source sentences
Summary
TNF-alpha (26.6 ± 3.05 pg/ml) (p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411707
08AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the lowest plasma pentraxin-3 among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, oxytocin gave the lowest blood level of the inflammation marker pentraxin-3 among the three treatments.
Peptide
Oxytocin
Outcome
DecreasePlasma pentraxin-3
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Measurements
Plasma pentraxin-3
2.7 ng/ml
DXR + OX
Source sentences
Summary
pentraxin-3 (2.7 ± 0.9 ng/ml) (p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411708
09AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the lowest plasma troponin T among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, oxytocin gave the lowest blood level of the heart injury marker troponin T among the three treatments.
Peptide
Oxytocin
Outcome
DecreasePlasma troponin T
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Myocardial injury · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Measurements
Plasma troponin T
1.4 pg/ml
DXR + OX
Source sentences
Summary
Troponin T (1.4 ± 0.08 pg/ml) (p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411709
10AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced cardiomyopathy, the oxytocin group had the lowest plasma pro-BNP among the three treatment groups.
In plain wordsIn rats with doxorubicin heart damage, oxytocin gave the lowest blood level of the heart strain marker pro-BNP among the three treatments.
Peptide
Oxytocin
Outcome
DecreasePlasma pro-BNP
Study
ratn: not reported in source
Doxorubicin-induced cardiomyopathy in male Sprague-Dawley rats
Comparator
Liraglutide and G-CSF groups
Outcome group
Heart function · Cardiovascular
Studied dose
160 μg/kg/day · intraperitoneal · 15 daysAs given in this study (rat).
Measurements
Plasma pro-BNP
11.1 pg/ml
DXR + OX
Source sentences
Summary
pro-BNP (11.1 ± 3.6 pg/ml) (p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this experimental animal study, we aimed to define therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in DXR-induced cardiomyopathy model.
Summary · context
Group 1 rats were assigned to a placebo group and was given with a 0.9% NaCl saline solution at a dose of 1 ml/kg/day i.p. (DXR + saline), Group 2 rats were given with 1.8 mg/kg/day of Liraglutide i.p. (DXR + LIR), Group 3 rats were given with 160 μg/kg/day oxytocin i.p. (DXR + OX), Group 4 rats wer…
Summary · context
All medications were given for 15 days.
Report a problemFND-3105411710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 2
9 Oct 2026, 03:05 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords